Abstract
A growing body of evidence supports the importance of functional imaging studies using single-photon emission tomography (SPECT) or positron emission tomography (PET) in neurology. In particular, Parkinson’s disease (PD) and other neurodegenerative disorders are useful disease models to understand the contribution of modern functional neuroimaging techniques. In this chapter, our aim is to address the principles of molecular imaging and also its pitfalls, with a focus on PD motor and nonmotor symptoms. From brain pathology to neurochemical pathology, from clinically unclear cases of parkinsonism to non-dopaminergic ligands and, finally, taking into account experimental tracers, we hope to cover key issues regarding the contribution of SPECT and PET in PD.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adams JR, van Netten H, Schulzer M, Mak E, Mckenzie J, Strongosky A et al (2005) PET in LRRK2 mutations: comparison to sporadic Parkinson’s disease and evidence for presymptomatic compensation. Brain 128(Pt 12):2777–2785. https://doi.org/10.1093/brain/awh607
Agarwal PA, Stoessl AJ (2013) Biomarkers for trials of neuroprotection in Parkinson’s disease. Mov Disord 28(1):71–85. https://doi.org/10.1002/mds.25065
Aiello M, Cavaliere C, Marchitelli R, D’Albore A, De Vita E, Salvatore M (2018) Hybrid PET/MRI methodology. Int Rev Neurobiol 141:97–128. https://doi.org/10.1016/bs.irn.2018.07.026
Akhtar RS, Xie SX, Chen YJ, Rick J, Gross RG, Nasrallah IM et al (2017) Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. PLoS One 12(5):e0177924. https://doi.org/10.1371/journal.pone.0177924
Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL (1997) Long-term changes of striatal dopamine D2 receptors in patients with Parkinson’s disease: a study with positron emission tomography and [11C]raclopride. Mov Disord 12(1):33–38. https://doi.org/10.1002/mds.870120107
Asahina M, Shinotoh H, Hirayama K, Suhara T, Shishido F, Inoue O, Tateno Y (1995) Hypersensitivity of cortical muscarinic receptors in Parkinson’s disease demonstrated by PET. Acta Neurol Scand 91(6):437–443
Asahina M, Suhara T, Shinotoh H, Inoue O, Suzuki K, Hattori T (1998) Brain muscarinic receptors in progressive supranuclear palsy and Parkinson’s disease: a positron emission tomographic study. J Neurol Neurosurg Psychiatry 65(2):155–163. https://doi.org/10.1136/jnnp.65.2.155
Asanuma K, Tang C, Ma Y, Dhawan V, Mattis P, Edwards C et al (2006) Network modulation in the treatment of Parkinson’s disease. Brain 129(Pt 10):2667–2678. https://doi.org/10.1093/brain/awl162
Asari S, Fujimoto K, Miyauchi A, Sato T, Nakano I, Muramatsu S (2011) Subregional 6-[18F]fluoro-ʟ-m-tyrosine uptake in the striatum in Parkinson’s disease. BMC Neurol 11:35. https://doi.org/10.1186/1471-2377-11-35
Au WL, Adams JR, Troiano AR, Stoessl AJ (2005) Parkinson’s disease: in vivo assessment of disease progression using positron emission tomography. Brain Res Mol Brain Res 134(1):24–33. https://doi.org/10.1016/j.molbrainres.2004.09.028
Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20(4):415–455. https://doi.org/10.1016/0022-510X(73)90175-5
Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG et al (2003) Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 60(12):1745–1748. https://doi.org/10.1001/archneur.60.12.1745
Bohnen NI, Müller MLTM, Koeppe RA, Studenski SA, Kilbourn MA, Frey KA, Albin RL (2009) History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 73(20):1670–1676. https://doi.org/10.1212/WNL.0b013e3181c1ded6
Bohnen NI, Müller MLTM, Kotagal V, Koeppe RA, Kilbourn MR, Gilman S et al (2012) Heterogeneity of cholinergic denervation in Parkinson’s disease without dementia. J Cereb Blood Flow Metab 32(8):1609–1617. https://doi.org/10.1038/jcbfm.2012.60
Bohnen NI, Kanel P, Zhou Z, Koeppe RA, Frey KA, Dauer WT et al (2019) Cholinergic system changes of falls and freezing of gait in Parkinson’s disease. Ann Neurol 85(4):538–549. https://doi.org/10.1002/ana.25430
Boileau I, Rusjan P, Houle S, Wilkins D, Tong J, Selby P et al (2008a) Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: is VMAT2 a stable dopamine neuron biomarker? J Neurosci 28(39):9850–9856. https://doi.org/10.1523/JNEUROSCI.3008-08.2008
Boileau I, Warsh JJ, Guttman M, Saint-Cyr JA, McCluskey T, Rusjan P et al (2008b) Elevated serotonin transporter binding in depressed patients with Parkinson’s disease: a preliminary PET study with [11C]DASB. Mov Disord 23(12):1776–1780. https://doi.org/10.1002/mds.22212
Bollen E, Prickaerts J (2012) Phosphodiesterases in neurodegenerative disorders. IUBMB Life 64(12):965–970. https://doi.org/10.1002/iub.1104
Boscutti GA, Rabiner E, Plisson C (2019) PET radioligands for imaging of the PDE10A in human: current status. Neurosci Lett 691:11–17. https://doi.org/10.1016/j.neulet.2018.08.006
Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211. https://doi.org/10.1016/S0197-4580(02)00065-9
Brück A, Aalto S, Nurmi E, Vahlberg T, Bergman J, Rinne JO (2006) Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson’s disease: a two-year follow-up study. Mov Disord 21(7):958–963. https://doi.org/10.1002/mds.20855
Brück A, Aalto S, Rauhala E, Bergman J, Marttila R, Rinne JO (2009) A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson’s disease shows nonlinear progression in the putamen. Mov Disord 24(7):1009–1015. https://doi.org/10.1002/mds.22484
Brundin P, Pogarell O, Hagell P, Piccini P, Widner H, Schrag A et al (2000) Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson’s disease. Brain 123(Pt 7):1380–1390. https://doi.org/10.1093/brain/123.7.1380
Buée L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PR (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33(1):95–130. https://doi.org/10.1016/S0165-0173(00)00019-9
Carlsson T, Carta M, Muñoz A, Mattsson B, Winkler C, Kirik D, Björklund A (2009) Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain 132(Pt 2):319–335. https://doi.org/10.1093/brain/awn305
Carta M, Carlsson T, Kirik D, Björklund A (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130(Pt 7):1819–1833. https://doi.org/10.1093/brain/awm082
Carta M, Carlsson T, Muñoz A, Kirik D, Björklund A (2010) Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson’s disease. Mov Disord 25(Suppl 1):S174–S179. https://doi.org/10.1002/mds.22792
Chaudhuri KR, Odin P, Antonini A, Martinez-Martin P (2011) Parkinson’s disease: the non-motor issues. Parkinsonism Relat Disord 17(10):717–723. https://doi.org/10.1016/j.parkreldis.2011.02.018
Chung EJ, Kim SJ (2015) (123)I-Metaiodobenzylguanidine myocardial scintigraphy in lewy body-related disorders: a literature review. J Mov Disord 8(2):55–66. https://doi.org/10.14802/jmd.15015
Colloby SJ, Pakrasi S, Firbank MJ, Perry EK, Piggott MA, Owens J et al (2006) In vivo SPECT imaging of muscarinic acetylcholine receptors using (R,R) 123I-QNB in dementia with Lewy bodies and Parkinson’s disease dementia. NeuroImage 33(2):423–429. https://doi.org/10.1016/j.neuroimage.2006.07.026
Constantinides VC, Paraskevas GP, Emmanouilidou E, Petropoulou O, Bougea A, Vekrellis K et al (2017) CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes. J Neurol Sci 382(September):91–95. https://doi.org/10.1016/j.jns.2017.09.039
De La Fuente-Fernández R, Furtado S, Guttman M, Furukawa Y, Lee CS, Calne DB et al (2003) VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET. Synapse (New York, NY) 49(1):20–28. https://doi.org/10.1002/syn.10199
de la Fuente-Fernández R, Sossi V, McCormick S, Schulzer M, Ruth TJ, Stoessl AJ (2009) Visualizing vesicular dopamine dynamics in Parkinson’s disease. Synapse (New York, NY) 63(8):713–716. https://doi.org/10.1002/syn.20653
de la Fuente-Fernández R, Schulzer M, Kuramoto L, Cragg J, Ramachandiran N, Au WL et al (2011) Age-specific progression of nigrostriatal dysfunction in Parkinson’s disease. Ann Neurol 69(5):803–810. https://doi.org/10.1002/ana.22284
de Paulis T (2003) The discovery of epidepride and its analogs as high-affinity radioligands for imaging extrastriatal dopamine D(2) receptors in human brain. Curr Pharm Des 9(8):673–696
DeJesus OT, Holden JE, Endres C, Murali D, Oakes TR, Shelton S et al (1992) Visualization of dopamine nerve terminals by positron tomography using [18F]fluoro-beta-fluoromethylene-m-tyrosine. Brain Res 597(1):151–154. https://doi.org/10.1016/0006-8993(92)91518-j
DeJesus OT, Flores LG, Murali D, Converse AK, Bartlett RM, Barnhart TE et al (2005) Aromatic L-amino acid decarboxylase turnover in vivo in rhesus macaque striatum: a microPET study. Brain Res 1054(1):55–60. https://doi.org/10.1016/j.brainres.2005.06.086
Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ, 11C-WAY 100635 PET Study (2003) Tremor in Parkinson’s disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 60(4):601–605
Doudet DJ, Chan GL, Jivan S, DeJesus OT, McGeer EG, English C et al (1999) Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-L-dopa versus 6-[18F]fluoro-L-m-tyrosine. J Cereb Blood Flow Metab 19(3):278–287. https://doi.org/10.1097/00004647-199903000-00006
Edison P, Ahmed I, Fan Z, Hinz R, Gelosa G, Ray Chaudhuri K et al (2013) Microglia, amyloid, and glucose metabolism in Parkinson’s disease with and without dementia. Neuropsychopharmacology 38(6):938–949. https://doi.org/10.1038/npp.2012.255
Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A et al (2019) Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology 92(7):329–337. https://doi.org/10.1212/WNL.0000000000006926
Fahn S (1999) Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs later L-DOPA. Arch Neurol 56(5):529–535. https://doi.org/10.1001/archneur.56.5.529
Fan Z, Aman Y, Ahmed I, Chetelat G, Landeau B, Ray Chaudhuri K et al (2015) Influence of microglial activation on neuronal function in Alzheimer’s and Parkinson’s disease dementia. Alzheimers Dement 11(6):608–21.e7. https://doi.org/10.1016/j.jalz.2014.06.016
Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114(Pt 5):2283–2301. https://doi.org/10.1136/jnnp.2007.131045
Fedorova TD, Seidelin LB, Knudsen K, Schacht AC, Geday J, Pavese N et al (2017) Decreased intestinal acetylcholinesterase in early Parkinson disease: an 11C-donepezil PET study. Neurology 88(8):775–781. https://doi.org/10.1212/WNL.0000000000003633
Feigin A, Fukuda M, Dhawan V, Przedborski S, Jackson-Lewis V, Mentis MJ et al (2001) Metabolic correlates of levodopa response in Parkinson’s disease. Neurology 57(11):2083–2088. https://doi.org/10.1212/wnl.57.11.2083
Felicio AC, Shih MC, Godeiro-Junior C, Andrade LAF, Bressan RA, Ferraz HB (2009) Molecular imaging studies in Parkinson disease: reducing diagnostic uncertainty. Neurologist 15(1):6–16. https://doi.org/10.1097/NRL.0b013e318183fdd8
Femminella GD, Ninan S, Atkinson R, Fan Z, Brooks DJ, Edison P (2016) Does microglial activation influence hippocampal volume and neuronal function in Alzheimer’s disease and Parkinson’s disease dementia? J Alzheimers Dis 51(4):1275–1289. https://doi.org/10.3233/JAD-150827
Fereshtehnejad S, Zeighami Y, Dagher A, Postuma RB (2017) Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression. Brain 140(7):1959–1976. https://doi.org/10.1093/brain/awx118
Firbank MJ, Yarnall AJ, Lawson RA, Duncan GW, Khoo TK, Petrides GS et al (2017) Cerebral glucose metabolism and cognition in newly diagnosed Parkinson’s disease: ICICLE-PD study. J Neurol Neurosurg Psychiatry 88(4):310–316. https://doi.org/10.1136/jnnp-2016-313918
Foffani G, Obeso JA (2018) A cortical pathogenic theory of Parkinson’s disease. Neuron 99(6):1116–1128. https://doi.org/10.1016/j.neuron.2018.07.028
Frankle WG, Huang Y, Hwang D, Talbot PS, Slifstein M, Van Heertum R et al (2004) Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans. J Nucl Med 45(4):682–694
Fujita M, Ichise M, Zoghbi SS, Liow J-S, Ghose S, Vines DC et al (2006) Widespread decrease of nicotinic acetylcholine receptors in Parkinson’s disease. Ann Neurol 59(1):174–177. https://doi.org/10.1002/ana.20688
Fukuda M, Mentis MJ, Ma Y, Dhawan V, Antonini A, Lang AE et al (2001) Networks mediating the clinical effects of pallidal brain stimulation for Parkinson’s disease: a PET study of resting-state glucose metabolism. Brain 124(Pt 8):1601–1609. https://doi.org/10.1093/brain/124.8.1601
Garcia-Garcia D, Clavero P, Gasca Salas C, Lamet I, Arbizu J, Gonzalez-Redondo R et al (2012) Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson’s disease. Eur J Nucl Med Mol Imaging 39(11):1767–1777. https://doi.org/10.1007/s00259-012-2198-5
GBD 2016 Parkinson’s Disease Collaborators (2018) Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17(11):939–953. https://doi.org/10.1016/S1474-4422(18)30295-3
Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A et al (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis 21(2):404–412. https://doi.org/10.1016/j.nbd.2005.08.002
Ghadery C, Best LA, Pavese N, Tai YF, Strafella AP (2019) PET evaluation of microglial activation in non-neurodegenerative brain diseases. Curr Neurol Neurosci Rep 19(7):38. https://doi.org/10.1007/s11910-019-0951-x
Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51(6):745–752. https://doi.org/10.1136/jnnp.51.6.745
Gill SS, Patel NK, Hotton GR, O’Sullivan K, McCarter R, Bunnage M et al (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9(5):589–595. https://doi.org/10.1038/nm850
Gilman S, Koeppe RA, Nan B, Wang C-N, Wang X, Junck L et al (2010) Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes. Neurology 74(18):1416–1423. https://doi.org/10.1212/WNL.0b013e3181dc1a55
Gjerløff T, Fedorova T, Knudsen K, Munk OL, Nahimi A, Jacobsen S et al (2015) Imaging acetylcholinesterase density in peripheral organs in Parkinson’s disease with 11C-donepezil PET. Brain 138(Pt 3):653–663. https://doi.org/10.1093/brain/awu369
Goldman JG, Postuma R (2014) Premotor and nonmotor features of Parkinson’s disease. Curr Opin Neurol 27(4):434–441. https://doi.org/10.1097/WCO.0000000000000112
Hammes J, Drzezga A, van Eimeren T (2018) The role of Tau imaging in parkinsonian disorders. Curr Neurol Neurosci Rep 18(12):86. https://doi.org/10.1007/s11910-018-0898-3
Hellwig S, Amtage F, Kreft A, Buchert R, Winz OH, Vach W et al (2012) [18F]FDG-PET is superior to [123I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology 79(13):1314–1322. https://doi.org/10.1212/WNL.0b013e31826c1b0a
Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23(6):837–844. https://doi.org/10.1002/mds.21956
Henderson EJ, Lord SR, Brodie MA, Gaunt DM, Lawrence AD, Close JCT et al (2016) Rivastigmine for gait stability in patients with Parkinson’s disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15(3):249–258. https://doi.org/10.1016/S1474-4422(15)00389-0
Hilker R, Schweitzer K, Coburger S, Ghaemi M, Weisenbach S, Jacobs AH et al (2005a) Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F18 activity. Arch Neurol 62(3):378–382. https://doi.org/10.1001/archneur.62.3.378
Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L et al (2005b) Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 65(11):1716–1722. https://doi.org/10.1212/01.wnl.0000191154.78131.f6
Hiraoka K, Okamura N, Funaki Y, Hayashi A, Tashiro M, Hisanaga K et al (2012) Cholinergic deficit and response to donepezil therapy in Parkinson’s disease with dementia. Eur Neurol 68(3):137–143. https://doi.org/10.1159/000338774
Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427–442
Holmstrand EC, Sesack SR (2011) Projections from the rat pedunculopontine and laterodorsal tegmental nuclei to the anterior thalamus and ventral tegmental area arise from largely separate populations of neurons. Brain Struct Funct 216(4):331–345. https://doi.org/10.1007/s00429-011-0320-2
Horti AG, Naik R, Foss CA, Minn I, Misheneva V, Du Y et al (2019) PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). Proc Natl Acad Sci U S A 116(5):1686–1691. https://doi.org/10.1073/pnas.1812155116
Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D (2007a) Metabolic brain networks associated with cognitive function in Parkinson’s disease. NeuroImage 34(2):714–723. https://doi.org/10.1016/j.neuroimage.2006.09.003
Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M et al (2007b) Changes in network activity with the progression of Parkinson’s disease. Brain 130(Pt 7):1834–1846. https://doi.org/10.1093/brain/awm086
Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D (2008) Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 70(16 Pt 2):1470–1477. https://doi.org/10.1212/01.wnl.0000304050.05332.9c
Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184. https://doi.org/10.1136/jnnp.55.3.181
Hughes AJ, Daniel SE, Blankson S, Lees AJ (1993) A clinicopathologic study of 100 cases of Parkinson’s disease. Arch Neurol 50(2):140–148. https://doi.org/10.1001/archneur.1993.00540020018011
Hughes AJ, Daniel SE, Lees AJ (2001) Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease. Neurology 57(8):1497–1499. https://doi.org/10.1212/WNL.57.8.1497
Hung ASM, Tsui TYM, Lam JCY, Wai MSM, Chan WM, Yew DT (2011) Serotonin and its receptors in the human CNS with new findings - a mini review. Curr Med Chem 18(34):5281–5288
Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM et al (2000) Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology 54(10):1916–1921. https://doi.org/10.1212/wnl.54.10.1916
Iannaccone S, Cerami C, Alessio M, Garibotto V, Panzacchi A, Olivieri S et al (2013) In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson’s disease. Parkinsonism Relat Disord 19(1):47–52. https://doi.org/10.1016/j.parkreldis.2012.07.002
Imon Y, Matsuda H, Ogawa M, Kogure D, Sunohara N (1999) SPECT image analysis using statistical parametric mapping in patients with Parkinson’s disease. J Nucl Med 40(10):1583–1589
Irwin DJ, Lee VM-Y, Trojanowski JQ (2013) Parkinson’s disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci 14(9):626–636. https://doi.org/10.1038/nrn3549
Jellinger KA (2003) Neuropathological spectrum of synucleinopathies. Mov Disord 18(S6):S2–S12. https://doi.org/10.1002/mds.10557
Jokinen P, Scheinin N, Aalto S, Någren K, Savisto N, Parkkola R et al (2010) [(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson’s disease with and without dementia. Parkinsonism Relat Disord 16(10):666–670. https://doi.org/10.1016/j.parkreldis.2010.08.021
Kägi G, Bhatia KP, Tolosa E (2010) The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry 81(1):5–12. https://doi.org/10.1136/jnnp.2008.157370
Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA et al (2007) Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. Lancet (London, England) 369(9579):2097–2105. https://doi.org/10.1016/S0140-6736(07)60982-9
Kas A, Bottlaender M, Gallezot JD, Vidailhet M, Villafane G, Grégoire MC et al (2009) Decrease of nicotinic receptors in the nigrostriatal system in Parkinson’s disease. J Cereb Blood Flow Metab 29(9):1601–1608. https://doi.org/10.1038/jcbfm.2009.74
Klein JC, Eggers C, Kalbe E, Weisenbach S, Hohmann C, Vollmar S et al (2010) Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 74(11):885–892. https://doi.org/10.1212/WNL.0b013e3181d55f61
Koga S, Ono M, Sahara N, Higuchi M, Dickson DW (2017) Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to α-synuclein pathology. Mov Disord 32(6):884–892. https://doi.org/10.1002/mds.27013
Koole M, Van Laere K, Ahmad R, Ceccarini J, Bormans G, Vandenberghe W (2017) Brain PET imaging of phosphodiesterase 10A in progressive supranuclear palsy and Parkinson’s disease. Mov Disord 32(6):943–945. https://doi.org/10.1002/mds.27005
Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH et al (2013) Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain 136(Pt 8):2419–2431. https://doi.org/10.1093/brain/awt192
Koshimori Y, Ko J-H, Mizrahi R, Rusjan P, Mabrouk R, Jacobs MF et al (2015) Imaging striatal microglial activation in patients with Parkinson’s disease. PLoS One 10(9):e0138721. https://doi.org/10.1371/journal.pone.0138721
Kotagal V, Albin RL, Müller MLTM, Koeppe RA, Chervin RD, Frey KA, Bohnen NI (2012) Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. Ann Neurol 71(4):560–568. https://doi.org/10.1002/ana.22691
Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP et al (1996) In vivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s disease. Ann Neurol 40(3):399–410. https://doi.org/10.1002/ana.410400309
Kuramoto L, Cragg J, Nandhagopal R, Mak E, Sossi V, de la Fuente-Fernández R et al (2013) The nature of progression in Parkinson’s disease: an application of non-linear, multivariate, longitudinal random effects modelling. PLoS One 8(10):e76595. https://doi.org/10.1371/journal.pone.0076595
Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R et al (2006) Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59(3):459–466. https://doi.org/10.1002/ana.20737
Langston JW (2006) The Parkinson’s complex: parkinsonism is just the tip of the iceberg. Ann Neurol 59(4):591–596. https://doi.org/10.1002/ana.20834
Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE et al (2000) In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson’s disease. Ann Neurol 47(4):493–503. https://doi.org/10.1002/1531-8249(200004)47:4<493::AID-ANA13>3.0.CO;2-4
Lee J-Y, Seo S, Lee JS, Kim H-J, Kim YK, Jeon BS (2015) Putaminal serotonergic innervation: monitoring dyskinesia risk in Parkinson disease. Neurology 85(10):853–860. https://doi.org/10.1212/WNL.0000000000001909
Lippert RN, Cremer AL, Edwin Thanarajah S, Korn C, Jahans-Price T, Burgeno LM et al (2019) Time-dependent assessment of stimulus-evoked regional dopamine release. Nat Commun 10(1):336. https://doi.org/10.1038/s41467-018-08143-4
Liu S-Y, Wile DJ, Fu JF, Valerio J, Shahinfard E, McCormick S et al (2018) The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson’s disease: a cross-sectional PET study. Lancet Neurol 17(4):309–316. https://doi.org/10.1016/S1474-4422(18)30032-2
Loane C, Wu K, Bain P, Brooks DJ, Piccini P, Politis M (2013) Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD. Neurology 80(20):1850–1855. https://doi.org/10.1212/WNL.0b013e318292a31d
Maetzler W, Reimold M, Liepelt I, Solbach C, Leyhe T, Schweitzer K et al (2008) [11C]PIB binding in Parkinson’s disease dementia. NeuroImage 39(3):1027–1033. https://doi.org/10.1016/j.neuroimage.2007.09.072
Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C et al (2009) Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 34(1):107–112. https://doi.org/10.1016/j.nbd.2008.12.008
Maillet A, Krack P, Lhommée E, Météreau E, Klinger H, Favre E et al (2016) The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson’s disease. Brain 139(Pt 9):2486–2502. https://doi.org/10.1093/brain/aww162
Marras C, Beck JC, Bower JH, Roberts E, Ritz B, Ross GW et al (2018) Prevalence of Parkinson’s disease across North America. NPJ Parkinsons Dis 4(1):21. https://doi.org/10.1038/s41531-018-0058-0
Martin WR, Palmer MR, Patlak CS, Calne DB (1989) Nigrostriatal function in humans studied with positron emission tomography. Ann Neurol 26(4):535–542. https://doi.org/10.1002/ana.410260407
Mashima K, Ito D, Kameyama M, Osada T, Tabuchi H, Nihei Y et al (2017) Extremely low prevalence of amyloid positron emission tomography positivity in Parkinson’s disease without dementia. Eur Neurol 77(5–6):231–237. https://doi.org/10.1159/000464322
Mazère J, Lamare F, Allard M, Fernandez P, Mayo W (2017) 123I-Iodobenzovesamicol SPECT imaging of cholinergic systems in dementia with lewy bodies. J Nucl Med 58(1):123–128. https://doi.org/10.2967/jnumed.116.176180
Melzer TR, Stark MR, Keenan RJ, Myall DJ, MacAskill MR, Pitcher TL et al (2019) Beta amyloid deposition is not associated with cognitive impairment in Parkinson’s disease. Front Neurol 10(April):391. https://doi.org/10.3389/fneur.2019.00391
Mencacci NE, Kamsteeg E-J, Nakashima K, R’Bibo L, Lynch DS, Balint B et al (2016) De novo mutations in PDE10A cause childhood-onset chorea with bilateral striatal lesions. Am J Hum Genet 98(4):763–771. https://doi.org/10.1016/j.ajhg.2016.02.015
Merchant KM, Cedarbaum JM, Brundin P, Dave KD, Eberling J, Espay AJ et al (2019) A proposed roadmap for Parkinson’s disease proof of concept clinical trials investigating compounds targeting alpha-synuclein. J Parkinsons Dis 9(1):31–61. https://doi.org/10.3233/JPD-181471
Marek KL, Seibyl JP, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B, Charney DS, van Dyck C, Hoffer PB, Innis RP (1996) [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology 46:231–237
Meyer PM, Strecker K, Kendziorra K, Becker G, Hesse S, Woelpl D et al (2009) Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry 66(8):866–877. https://doi.org/10.1001/archgenpsychiatry.2009.106
Moore RY, Whone AL, McGowan S, Brooks DJ (2003) Monoamine neuron innervation of the normal human brain: an 18F-DOPA PET study. Brain Res 982(2):137–145. https://doi.org/10.1016/s0006-8993(03)02721-5
Moore RY, Whone AL, Brooks DJ (2008) Extrastriatal monoamine neuron function in Parkinson’s disease: an 18F-dopa PET study. Neurobiol Dis 29(3):381–390. https://doi.org/10.1016/j.nbd.2007.09.004
Moro E, Hamani C, Poon Y-Y, Al-Khairallah T, Dostrovsky JO, Hutchison WD, Lozano AM (2010) Unilateral pedunculopontine stimulation improves falls in Parkinson’s disease. Brain 133(Pt 1):215–224. https://doi.org/10.1093/brain/awp261
Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ (1998) Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 64(3):314–319. https://doi.org/10.1136/jnnp.64.3.314
Muchowski PJ (2002) Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones? Neuron 35(1):9–12
Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T et al (2008) Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 131(Pt 12):3380–3394. https://doi.org/10.1093/brain/awn235
Muñoz A, Carlsson T, Tronci E, Kirik D, Björklund A, Carta M (2009) Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Exp Neurol 219(1):298–307. https://doi.org/10.1016/j.expneurol.2009.05.033
Mure H, Hirano S, Tang CC, Isaias IU, Antonini A, Ma Y et al (2011) Parkinson’s disease tremor-related metabolic network: characterization, progression, and treatment effects. NeuroImage 54(2):1244–1253. https://doi.org/10.1016/j.neuroimage.2010.09.028
Murugan NA, Chiotis K, Rodriguez-Vieitez E, Lemoine L, Ågren H, Nordberg A (2019) Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging. Eur J Nucl Med Mol Imaging 46(6):1369–1382. https://doi.org/10.1007/s00259-019-04305-8
Nahimi A, Sommerauer M, Kinnerup MB, Østergaard K, Winterdahl M, Jacobsen J et al (2018) Noradrenergic deficits in Parkinson disease imaged with 11C-MeNER. J Nucl Med 59(4):659–664. https://doi.org/10.2967/jnumed.117.190975
Nakamura T, Dhawan V, Chaly T, Fukuda M, Ma Y, Breeze R et al (2001) Blinded positron emission tomography study of dopamine cell implantation for Parkinson’s disease. Ann Neurol 50(2):181–187
Nandhagopal R, Mak E, Schulzer M, McKenzie J, McCormick S, Sossi V et al (2008) Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. Neurology 71(22):1790–1795. https://doi.org/10.1212/01.wnl.0000335973.66333.58
Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, Lee CS et al (2009) Longitudinal progression of sporadic Parkinson’s disease: a multi-tracer positron emission tomography study. Brain 132(Pt 11):2970–2979. https://doi.org/10.1093/brain/awp209
Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, McKenzie J et al (2011) Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson’s disease. Brain 134(Pt 11):3290–3298. https://doi.org/10.1093/brain/awr233
Narayanaswami V, Dahl K, Bernard-Gauthier V, Josephson L, Cumming P, Vasdev N (2018) Emerging PET radiotracers and targets for imaging of neuroinflammation in neurodegenerative diseases: outlook beyond TSPO. Mol Imaging 17:1536012118792317. https://doi.org/10.1177/1536012118792317
Niccolini F, Foltynie T, Reis Marques T, Muhlert N, Tziortzi AC, Searle GE et al (2015) Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson’s disease. Brain 138(Pt 10):3003–3015. https://doi.org/10.1093/brain/awv219
Nishi A, Kuroiwa M, Miller DB, O’Callaghan JP, Bateup HS, Shuto T et al (2008) Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci 28(42):10460–10471. https://doi.org/10.1523/JNEUROSCI.2518-08.2008
Nurmi E, Ruottinen HM, Bergman J, Haaparanta M, Solin O, Sonninen P, Rinne JO (2001) Rate of progression in Parkinson’s disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord 16(4):608–615. https://doi.org/10.1002/mds.1139
Oishi N, Hashikawa K, Yoshida H, Ishizu K, Ueda M, Kawashima H et al (2007) Quantification of nicotinic acetylcholine receptors in Parkinson’s disease with (123)I-5IA SPECT. J Neurol Sci 256(1–2):52–60. https://doi.org/10.1016/j.jns.2007.02.014
Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF et al (2003) A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol 54(3):403–414. https://doi.org/10.1002/ana.10720
Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H (1999) (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson’s disease. J Neurol Neurosurg Psychiatry 67(2):189–194. https://doi.org/10.1136/jnnp.67.2.189
Orimo S, Suzuki M, Inaba A, Mizusawa H (2012) 123I-MIBG myocardial scintigraphy for differentiating Parkinson’s disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat Disord 18(5):494–500. https://doi.org/10.1016/j.parkreldis.2012.01.009
Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T (2005) Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol 57(2):168–175. https://doi.org/10.1002/ana.20338
Owen DRJ, Piccini P, Matthews PM (2011) Towards molecular imaging of multiple sclerosis. Mult Scler 17(3):262–272. https://doi.org/10.1177/1352458510390070
Owen DR, Guo Q, Kalk NJ, Colasanti A, Kalogiannopoulou D, Dimber R et al (2014) Determination of [(11)C]PBR28 binding potential in vivo: a first human TSPO blocking study. J Cereb Blood Flow Metab 34(6):989–994. https://doi.org/10.1038/jcbfm.2014.46
Pagano G, Niccolini F, Wilson H, Yousaf T, Khan NL, Martino D et al (2019) Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson’s disease. Mov Disord 34(10):1505–1515. https://doi.org/10.1002/mds.27733
Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 284(15):1931–1938. https://doi.org/10.1001/jama.284.15.1931
Pavese N, Metta V, Bose SK, Chaudhuri KR, Brooks DJ (2010) Fatigue in Parkinson’s disease is linked to striatal and limbic serotonergic dysfunction. Brain 133(11):3434–3443. https://doi.org/10.1093/brain/awq268
Pavese N, Rivero-Bosch M, Lewis SJ, Whone AL, Brooks DJ (2011) Progression of monoaminergic dysfunction in Parkinson’s disease: a longitudinal 18F-dopa PET study. NeuroImage 56(3):1463–1468. https://doi.org/10.1016/j.neuroimage.2011.03.012
Pavese N, Simpson BS, Metta V, Ramlackhansingh A, Chaudhuri KR, Brooks DJ (2012) [18F]FDOPA uptake in the raphe nuclei complex reflects serotonin transporter availability. A combined [18F]FDOPA and [11C]DASB PET study in Parkinson’s disease. NeuroImage 59(2):1080–1084. https://doi.org/10.1016/j.neuroimage.2011.09.034
Perez-Soriano A, Arena JE, Dinelle K, Miao Q, McKenzie J, Neilson N et al (2017) PBB3 imaging in Parkinsonian disorders: evidence for binding to tau and other proteins. Mov Disord 32(7):1016–1024. https://doi.org/10.1002/mds.27029
Petrou M, Dwamena BA, Foerster BR, Maceachern MP, Bohnen NI, Müller ML et al (2015) Amyloid deposition in Parkinson’s disease and cognitive impairment: a systematic review. Mov Disord 30(7):928–935. https://doi.org/10.1002/mds.26191
Piccini PP (2003) Dopamine transporter: basic aspects and neuroimaging. Mov Disord 18(Suppl. 7):S3–S8. https://doi.org/10.1002/mds.10571
Pinborg LH, Videbaek C, Ziebell M, Mackeprang T, Friberg L, Rasmussen H et al (2007) [123I]Epidepride binding to cerebellar dopamine D2/D3 receptors is displaceable: implications for the use of cerebellum as a reference region. NeuroImage 34(4):1450–1453. https://doi.org/10.1016/j.neuroimage.2006.11.003
Politis M, Wu K, Loane C, Turkheimer FE, Molloy S, Brooks DJ, Piccini P (2010) Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 75(21):1920–1927. https://doi.org/10.1212/WNL.0b013e3181feb2ab
Politis M, Loane C, Wu K, Brooks DJ, Piccini P (2011) Serotonergic mediated body mass index changes in Parkinson’s disease. Neurobiol Dis 43(3):609–615. https://doi.org/10.1016/j.nbd.2011.05.009
Politis M, Pagano G, Niccolini F (2017) Imaging in Parkinson’s disease. Int Rev Neurobiol 132(C):233–274. https://doi.org/10.1016/bs.irn.2017.02.015
Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel WH et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12):1591–1601. https://doi.org/10.1002/mds.26424
Postuma RB, Poewe W, Litvan I, Lewis S, Lang AE, Halliday G et al (2018) Validation of the MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 33(10):1601–1608. https://doi.org/10.1002/mds.27362
Pysz MA, Gambhir SS, Willmann JK (2010) Molecular imaging: current status and emerging strategies. Clin Radiol 65(7):500–516. https://doi.org/10.1016/j.crad.2010.03.011
Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128(Pt 6):1314–1322. https://doi.org/10.1093/brain/awh445
Rinne JO, Laihinen A, Någren K, Bergman J, Solin O, Haaparanta M et al (1990) PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson’s disease. J Neurosci Res 27(4):494–499. https://doi.org/10.1002/jnr.490270409
Rogers JD, Brogan D, Mirra SS (1985) The nucleus basalis of Meynert in neurological disease: a quantitative morphological study. Ann Neurol 17(2):163–170. https://doi.org/10.1002/ana.410170210
Roussakis A-A, Politis M, Towey D, Piccini P (2016) Serotonin-to-dopamine transporter ratios in Parkinson disease: relevance for dyskinesias. Neurology 86(12):1152–1158. https://doi.org/10.1212/WNL.0000000000002494
Rylander D, Parent M, O’Sullivan SS, Dovero S, Lees AJ, Bezard E et al (2010) Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol 68(5):619–628. https://doi.org/10.1002/ana.22097
Sancesario G, Morrone LA, D’Angelo V, Castelli V, Ferrazzoli D, Sica F et al (2014) Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: reduced synthesis or increased catabolism? Neurochem Int 79:44–56. https://doi.org/10.1016/j.neuint.2014.10.004
Saulin A, Savli M, Lanzenberger R (2012) Serotonin and molecular neuroimaging in humans using PET. Amino Acids 42(6):2039–2057. https://doi.org/10.1007/s00726-011-1078-9
Schapira AH, Gu M, Taanman JW, Tabrizi SJ, Seaton T, Cleeter M, Cooper JM (1998) Mitochondria in the etiology and pathogenesis of Parkinson’s disease. Ann Neurol 44(3 Suppl 1):S89–S98
Schrag A, Schott JM (2006) Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol 5(4):355–363. https://doi.org/10.1016/S1474-4422(06)70411-2
Shah N, Frey KA, Müller MLTM, Petrou M, Kotagal V, Koeppe RA et al (2016) Striatal and cortical β-amyloidopathy and cognition in Parkinson’s disease. Mov Disord 31(1):111–117. https://doi.org/10.1002/mds.26369
Shih MC, Felicio AC, de Oliveira Godeiro-Junior C, de Carvalho Aguiar P, de Andrade LAF, Ferraz HB, Bressan RA (2007) Molecular imaging in hereditary forms of parkinsonism. Eur J Neurol 14(4):359–368. https://doi.org/10.1111/j.1468-1331.2007.01691.x
Shimada H, Hirano S, Shinotoh H, Aotsuka A, Sato K, Tanaka N et al (2009) Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 73(4):273–278. https://doi.org/10.1212/WNL.0b013e3181ab2b58
Shinotoh H, Inoue O, Hirayama K, Aotsuka A, Asahina M, Suhara T et al (1993) Dopamine D1 receptors in Parkinson’s disease and striatonigral degeneration: a positron emission tomography study. J Neurol Neurosurg Psychiatry 56(5):467–472. https://doi.org/10.1136/jnnp.56.5.467
Shinotoh H, Namba H, Yamaguchi M, Fukushi K, Nagatsuka S, Iyo M et al (1999) Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson’s disease and progressive supranuclear palsy. Ann Neurol 46(1):62–69. https://doi.org/10.1002/1531-8249(199907)46:1<62::AID-ANA10>3.0.CO;2-P
Smith R, Wu K, Hart T, Loane C, Brooks DJ, Björklund A et al (2015) The role of pallidal serotonergic function in Parkinson’s disease dyskinesias: a positron emission tomography study. Neurobiol Aging 36(4):1736–1742. https://doi.org/10.1016/j.neurobiolaging.2014.12.037
Sommerauer M, Fedorova TD, Hansen AK, Knudsen K, Otto M, Jeppesen J et al (2018a) Evaluation of the noradrenergic system in Parkinson’s disease: an 11C-MeNER PET and neuromelanin MRI study. Brain 141(2):496–504. https://doi.org/10.1093/brain/awx348
Sommerauer M, Hansen AK, Parbo P, Fedorova TD, Knudsen K, Frederiksen Y et al (2018b) Decreased noradrenaline transporter density in the motor cortex of Parkinson’s disease patients. Mov Disord 33(6):1006–1010. https://doi.org/10.1002/mds.27411
Sossi V (2018) Advances in PET methodology. In: International review of neurobiology, vol 141, 1st edn. Elsevier Inc., Amsterdam, pp 3–30. https://doi.org/10.1016/bs.irn.2018.07.034
Sossi V, de La Fuente-Fernández R, Holden JE, Doudet DJ, McKenzie J, Stoessl AJ, Ruth TJ (2002) Increase in dopamine turnover occurs early in Parkinson’s disease: evidence from a new modeling approach to PET 18 F-fluorodopa data. J Cereb Blood Flow Metab 22(2):232–239. https://doi.org/10.1097/00004647-200202000-00011
Sossi V, de la Fuente-Fernández R, Nandhagopal R, Schulzer M, McKenzie J, Ruth TJ et al (2010) Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. Mov Disord 25(16):2717–2723. https://doi.org/10.1002/mds.23356
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388(6645):839–840. https://doi.org/10.1038/42166
Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC (2013) How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale: comparison with the unified Parkinson’s disease rating scale. Mov Disord 28(5):668–670. https://doi.org/10.1002/mds.25383
Stoessl AJ (2011) Neuroimaging in Parkinson’s disease. Neurotherapeutics 8(1):72–81. https://doi.org/10.1007/s13311-010-0007-z
Stoessl AJ (2012) Neuroimaging in Parkinson’s disease: from pathology to diagnosis. Parkinsonism Relat Disord 18(Suppl 1):S55–S59. https://doi.org/10.1016/S1353-8020(11)70019-0
Stoessl AJ, Lehericy S, Strafella AP (2014) Imaging insights into basal ganglia function, Parkinson’s disease, and dystonia. Lancet (London, England) 384(9942):532–544. https://doi.org/10.1016/S0140-6736(14)60041-6
Stokholm MG, Iranzo A, Østergaard K, Serradell M, Otto M, Svendsen KB et al (2017) Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurol 16(10):789–796. https://doi.org/10.1016/S1474-4422(17)30173-4
Strafella AP, Bohnen NI, Perlmutter JS, Eidelberg D, Pavese N, Van Eimeren T et al (2017) Molecular imaging to track Parkinson’s disease and atypical parkinsonisms: new imaging frontiers. Mov Disord 32(2):181–192. https://doi.org/10.1002/mds.26907
Szabo Z, Kao PF, Scheffel U, Suehiro M, Mathews WB, Ravert HT et al (1995) Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)McN5652. Synapse (New York, NY) 20(1):37–43. https://doi.org/10.1002/syn.890200107
Tang CC, Poston KL, Dhawan V, Eidelberg D (2010) Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson’s disease. J Neurosci 30(3):1049–1056. https://doi.org/10.1523/JNEUROSCI.4188-09.2010
Tateno F, Sakakibara R, Kishi M, Ogawa E, Terada H, Ogata T, Haruta H (2011) Sensitivity and specificity of metaiodobenzylguanidine (MIBG) myocardial accumulation in the diagnosis of Lewy body diseases in a movement disorder clinic. Parkinsonism Relat Disord 17(5):395–397. https://doi.org/10.1016/j.parkreldis.2011.02.001
Tatsch K, Poepperl G (2012) Quantitative approaches to dopaminergic brain imaging. Q J Nucl Med Mol Imaging 56(1):27–38
Terada T, Yokokura M, Yoshikawa E, Futatsubashi M, Kono S, Konishi T et al (2016) Extrastriatal spreading of microglial activation in Parkinson’s disease: a positron emission tomography study. Ann Nucl Med 30(8):579–587. https://doi.org/10.1007/s12149-016-1099-2
Thobois S, Vingerhoets F, Fraix V, Xie-Brustolin J, Mollion H, Costes N et al (2004) Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study. Arch Neurol 61(11):1705–1709. https://doi.org/10.1001/archneur.61.11.1705
Tomše P, Jensterle L, Grmek M, Zaletel K, Pirtošek Z, Dhawan V et al (2017) Abnormal metabolic brain network associated with Parkinson’s disease: replication on a new European sample. Neuroradiology 59(5):507–515. https://doi.org/10.1007/s00234-017-1821-3
Tondo G, Esposito M, Dervenoulas G, Wilson H, Politis M, Pagano G (2019) Hybrid PET-MRI applications in movement disorders. Int Rev Neurobiol 144:211–257. https://doi.org/10.1016/bs.irn.2018.10.003
Van Weehaeghe D, Koole M, Schmidt ME, Deman S, Jacobs AH, Souche E et al (2019) [11C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson’s disease and healthy volunteers. Eur J Nucl Med Mol Imaging 46(10):2051–2064. https://doi.org/10.1007/s00259-019-04369-6
Vander Borght TM, Kilbourn MR, Koeppe RA, DaSilva JN, Carey JE, Kuhl DE, Frey KA (1995) In vivo imaging of the brain vesicular monoamine transporter. J Nucl Med 36(12):2252–2260. https://doi.org/10.1096/fj.00-0204rev
Vander Borght T, Minoshima S, Giordani B, Foster NL, Frey KA, Berent S et al (1997) Cerebral metabolic differences in Parkinson’s and Alzheimer’s diseases matched for dementia severity. J Nucl Med 38(5):797–802
Varnäs K, Cselényi Z, Jucaite A, Halldin C, Svenningsson P, Farde L, Varrone A (2019) PET imaging of [11C]PBR28 in Parkinson’s disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding. Eur J Nucl Med Mol Imaging 46(2):367–375. https://doi.org/10.1007/s00259-018-4161-6
Varrone A, Halldin C (2010) Molecular imaging of the dopamine transporter. J Nucl Med 51(9):1331–1334. https://doi.org/10.2967/jnumed.109.065656
Vingerhoets FJG, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB (1994) Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 36(5):759–764. https://doi.org/10.1002/ana.410360512
Volkow ND, Fowler JS, Wang GJ, Logan J, Schlyer D, MacGregor R et al (1994) Decreased dopamine transporters with age in health human subjects. Ann Neurol 36(2):237–239. https://doi.org/10.1002/ana.410360218
Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C et al (2003) Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54(1):93–101. https://doi.org/10.1002/ana.10609
Whone A, Luz M, Boca M, Woolley M, Mooney L, Dharia S et al (2019) Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson’s disease. Brain 142(3):512–525. https://doi.org/10.1093/brain/awz023
Wichmann T (2019) Changing views of the pathophysiology of Parkinsonism. Mov Disord 34(8):1130–1143. https://doi.org/10.1002/mds.27741
Wichmann T, DeLong MR, Guridi J, Obeso JA (2011) Milestones in research on the pathophysiology of Parkinson’s disease. Mov Disord 26(6):1032–1041. https://doi.org/10.1002/mds.23695
Wile DJ, Agarwal PA, Schulzer M, Mak E, Dinelle K, Shahinfard E et al (2017) Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies. Lancet Neurol 16(5):351–359. https://doi.org/10.1016/S1474-4422(17)30056-X
Wilson H, Giordano B, Turkheimer FE, Chaudhuri KR, Politis M (2018) Serotonergic dysregulation is linked to sleep problems in Parkinson’s disease. NeuroImage Clin 18:630–637. https://doi.org/10.1016/j.nicl.2018.03.001
Wilson H, Dervenoulas G, Pagano G, Koros C, Yousaf T, Picillo M et al (2019) Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study. Lancet Neurol 18(8):748–775. https://doi.org/10.1016/S1474-4422(19)30140-1
Winer JR, Maass A, Pressman P, Stiver J, Schonhaut DR, Baker SL et al (2017) Associations between tau, β-amyloid, and cognition in Parkinson disease. JAMA Neurol 94702:1–9. https://doi.org/10.1001/jamaneurol.2017.3713
Wu L, Liu F-T, Ge J-J, Zhao J, Tang Y-L, Yu W-B et al (2018) Clinical characteristics of cognitive impairment in patients with Parkinson’s disease and its related pattern in 18F-FDG PET imaging. Hum Brain Mapp 39(12):4652–4662. https://doi.org/10.1002/hbm.24311
Yarnall A, Rochester L, Burn DJ (2011) The interplay of cholinergic function, attention, and falls in Parkinson’s disease. Mov Disord 26(14):2496–2503. https://doi.org/10.1002/mds.23932
Yoshita M, Hayashi M, Hirai S (1998) Decreased myocardial accumulation of 123I-meta-iodobenzyl guanidine in Parkinson’s disease. Nucl Med Commun 19(2):137–142
Acknowledgements
Dr. M. Matarazzo was supported by a Clinical Research Fellowship Award from Parkinson Canada. Dr. A. J. Stoessl is supported by the Michael J. Fox Foundation, the Weston Brain Institute and the Canada Research Chairs Program. We gratefully acknowledge the assistance of Nasim Vafai for the image processing and generating the figures.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Matarazzo, M., Felicio, A.C., Stoessl, A.J. (2021). Parkinson’s Disease. In: Dierckx, R.A.J.O., Otte, A., de Vries, E.F.J., van Waarde, A., Leenders, K.L. (eds) PET and SPECT in Neurology. Springer, Cham. https://doi.org/10.1007/978-3-030-53168-3_24
Download citation
DOI: https://doi.org/10.1007/978-3-030-53168-3_24
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-53167-6
Online ISBN: 978-3-030-53168-3
eBook Packages: MedicineMedicine (R0)